Investors

Investors

Company Information

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach for the discovery, development and manufacture of monoclonal antibodies that modulate targets of interest. In addition, the Company’s cancer vaccine program includes three proprietary platforms focused on individualized and off-the-shelf vaccines uniquely designed for each patient. Agenus’ broad portfolio of novel checkpoint and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. The Company has formed collaborations with Merck and Incyte to discover and develop multiple checkpoint antibodies.

Press Releases
Sep 18, 2020
160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive patients 155 patient balstilimab (PD-1) + zalifrelimab (CTLA-4) combination trial achieves response rates of 22% in all patients and 27% in PD-L1 positive patients

btn News

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

btn Stock

SEC Filings

Form Description Filing date View
S-1

Registration statement for face-amount certificate companies

View HTML
S-1/A

Amended Registration statement for face-amount certificate companies

View HTML
8-A12G

Registration of certain classes of securities 12(g) of the Securities Exchange Act

View HTML
S-1/A

Amended Registration statement for face-amount certificate companies

View HTML

Data provided by Kaleidoscope.

btn SEC